Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (DHFR) mutant alleles

American Journal of Tropical Medicine and Hygiene

Volumn 75, Issue 3, 2006, Pages 396-401

  Tahar, Rachida ^a,b   Basco, Leonardo K ^a,b  

^a Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

^b Laboratoire de Recherche sur le Paludisme Yaounde   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; PRIMER DNA;

ALLELE; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; ENZYME ANALYSIS; GENE AMPLIFICATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MUTATIONAL ANALYSIS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; ANIMAL; CAMEROON; ENZYMOLOGY; EPIDEMIOLOGY; GENETICS; MALARIA FALCIPARUM; MUTATION; NUCLEOTIDE SEQUENCE;

PLASMODIUM FALCIPARUM;

ALLELES; ANIMALS; BASE SEQUENCE; CAMEROON; DNA PRIMERS; EPIDEMIOLOGY, MOLECULAR; HUMANS; MALARIA, FALCIPARUM; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 33750586478     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2006.75.396     Document Type: Article

References (29)

1. World Health Organization, 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization: Geneva. WHO/HTM/RBM/2003.50.
2. White NJ, 2004. Antimalarial drug resistance. J Clin Invest 113: 1084-1092.
3. Ringwald P, Basco LK, 1999. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaoundé, Cameroon. Bull World Health Org 77: 34-43.
4. Duraisingh MT, Roper C, Walliker D, Warhurst DC, 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdrl gene of Plasmodium falciparum. Mol Microbiol 36: 955-961.
5. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF, 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403: 906-909.
6. Ringwald P, Same Ekobo A, Keundjian A, Kedy Mangamba D, Basco LK, 2000. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part I: Surveillance in vitro et in vivo de la résistance de Plasmodium falciparum a la chloroquine entre 1994 et 1999 à Yaoundé, Cameroun. Trop Med Int Health 5: 612-619.
7. Basco LK, Foumane Ngane V, Ndounga M, Same-Ekobo A, Youmba JC, Okalla Abodo RT, Soula G, 2006. Molecular epidemiology of malaria in Cameroon. XXI Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 75: 388-395.
8. Basco LK( 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs Used for self-medication. Am J Trop Med Hyg 70: 245-250.
9. Basco LK, Tahar R, Ringwald P, 1998. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother 42: 1811-1814.
10. Basco LK, Ringwald P, 2000. Molecular epidemiology of malaria in Yaoundé, Cameroon. VI. Sequence variations in the Plus modium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg 62: 271-276.
11. Basco LK, Tahar R, Keundjian A, Ringwald P, 2000. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 182: 624-628.
12. Bonnet S, Paul REI, Gouagna C, Safeukui I, Meunier JY, Gounoue R, Boudin C, 2002. Level and dynamics of malaria transmission and morbidity in an equatorial area of South Cameroon. Trop Med Int Health 7: 249-256.
13. Henning L, Felger I, Beck HP, 1999. Rapid DNA extraction for molecular epidemiological studies of malaria. Acta Trop 72: 149-155.
14. Basco LK, Ndounga M, Tejiokem M, Foumane Ngane V, Youmba JC, Ringwald P, Soula G, 2002. Molecular epidemiology of malaria in Cameroon. XI. Geographic distribution of Plasmodium falciparum isolates with dihydrofolate reductase gene mutations in southern and central Cameroon. Am J Trop Med Hyg 67: 378-382.
15. Eldin de Pécoulas P, Basco LK, Abdallah B, Djé MK, Le Bras J, Mazabraud A, 1995. Plasmodium falciparum: Detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol 80: 483-487.
16. Hyde JE, 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 48: 45-59.
17. Foote SJ, Galatas D, Cowman AF, 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87: 3014-3017.
18. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
19. Ringwald P, Keundjian A, Same Ekobo A, Basco LK, 2000. Chimioresistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part 2: Evaluation de l'efficacité de l'amodiaquine et de l'association sulfadoxine-pyriméthamine pour le traitement de l'accès palustre simple à Plasmodium falciparum à Yaoundé, Cameroun. Trop Med Int Health 5: 620-627.
20. Ndounga M, Basco LK, Ringwald P, 2001. Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg 95: 55-57.
21. Basco LK, Ringwald P, 1999. Molecular epidemiology of malaria in Yaoundé, Cameroon. IV. Evolution of pyrimethamine resistance between 1994 and 1998. Am J Trop Med Hyg 61: 802-806.
22. Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance. Am J Trop Med Hyg 69: 174-178.
23. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44: 991-996.
24. Mockenhaupt FP, Bousema JT, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, Otchwemah RN, Sauerwein RW, Bienzle U, 2005. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine- pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health 10: 901-908.
25. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RAG, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
26. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G, 2003. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 69: 247-252.
27. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, Rosenthal PJ, 2004. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg 71: 758-763.
28. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H, 2004. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 71: 696-702.
29. Talisuna AO, Nalunkuma-Kazibwe A, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, Egwang TG, D'Alessandro U, 2004. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol 4: 321-327.